KAM
REGN icon

Krensavage Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Krensavage Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.09M Hold
4,000
– – 1.21% 16
2025
Q4 		$3.09M Hold
4,000
– – 1.09% 15
2025
Q3 		$2.25M Hold
4,000
– – 0.96% 15
2025
Q2 		$2.1M Buy
+4,000
New +$2.23M 1.11% 15
2024
Q4 		– Sell
-353
Closed -$371K – 13
2024
Q3 		$371K Sell
353
-7,500
-96% -$8.35M 0.21% 12
2024
Q2 		$8.25M Sell
7,853
-4,641
-37% -$4.5M 3.79% 9
2024
Q1 		$12M Sell
12,494
-34,762
-74% -$33.1M 5.33% 8
2023
Q4 		$41.5M Hold
47,256
– – 14.73% 4
2023
Q3 		$38.9M Sell
47,256
-11,932
-20% -$9.38M 14.32% 4
2023
Q2 		$42.5M Sell
59,188
-300
-0.5% -$231K 13.47% 3
2023
Q1 		$48.9M Sell
59,488
-615
-1% -$464K 14.84% 2
2022
Q4 		$43.4M Sell
60,103
-786
-1% -$580K 13.4% 3
2022
Q3 		$41.9M Buy
60,889
+505
+0.8% +$318K 13.36% 3
2022
Q2 		$35.7M Sell
60,384
-6,496
-10% -$4.22M 11.8% 3
2022
Q1 		$46.7M Sell
66,880
-2,200
-3% -$1.39M 16.1% 1
2021
Q4 		$43.6M Sell
69,080
-4,063
-6% -$2.5M 15.13% 2
2021
Q3 		$44.3M Sell
73,143
-8,961
-11% -$5.56M 13.89% 3
2021
Q2 		$45.9M Sell
82,104
-594
-0.7% -$301K 15.57% 1
2021
Q1 		$39.1M Buy
82,698
+498
+0.6% +$242K 13.54% 4
2020
Q4 		$39.7M Sell
82,200
-58
-0.1% -$31.3K 11.6% 4
2020
Q3 		$46M Buy
82,258
+2,567
+3% +$1.56M 14.66% 1
2020
Q2 		$49.7M Sell
79,691
-7,126
-8% -$4.04M 13.52% 3
2020
Q1 		$42.4M Sell
86,817
-17,603
-17% -$7.26M 13.64% 2
2019
Q4 		$39.2M Buy
+104,420
New +$35.1M 13.38% 2

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Krensavage Asset Management's REGN Position: Q1 2026 in Review

Krensavage Asset Management held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 4,000 shares worth $3.09M. The position accounts for 1.21% of the portfolio, ranked #16.

Krensavage Asset Management first reported a position in REGN in Q4 2019 and has held it in 24 quarters since. The position peaked at $49.7M in Q2 2020. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Krensavage Asset Management held 4,000 shares of Regeneron Pharmaceuticals worth $3.09M as of Q1 2026.
  • Krensavage Asset Management left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
  • Regeneron Pharmaceuticals made up 1.21% of Krensavage Asset Management's portfolio in Q1 2026, its #16 holding.
  • Krensavage Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2019 and has held it in 24 quarters since.
  • Krensavage Asset Management's Regeneron Pharmaceuticals position peaked at $49.7M in Q2 2020.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Krensavage Asset Management's 13F filing for Q1 2026, filed 15 May 2026.